Genetic variability in the multidrug resistance associated protein-1 (abcc1/mrp1) predicts hematological toxicity in breast cancer patients receiving (neo-)adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide (fec)

Annals of Oncology

Volumn 24, Issue 6, 2013, Pages 1513-1525

  Vulsteke, C ^a   Lambrechts, D ^b,c   Dieudonne A ^d   Hatse, S ^a   Brouwers, B ^a   van Brussel, T ^b,c   Neven, P ^d   Belmans, A ^d   Schoffski P ^a,d   Paridaens, R ^a,d   Wildiers, H ^a,d  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^c UNIVERSITY OF LEUVEN   (Belgium)

^d UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

ABCC1; Breast cancer; Febrile neutropenia; FEC chemotherapy; MRP1; Single nucleotide polymorphisms

Indexed keywords

CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; MULTIDRUG RESISTANCE PROTEIN 1;

ABCC1 GENE; ADJUVANT CHEMOTHERAPY; ADULT; ALLELE; ANEMIA; ARTICLE; BLOOD TOXICITY; BREAST CANCER; CANCER PATIENT; COHORT ANALYSIS; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG HYPERSENSITIVITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GENETIC ASSOCIATION; GENETIC SELECTION; GENETIC VARIABILITY; GENOTYPING TECHNIQUE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MRP1 GENE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTOPENIA; VOMITING;

ABCC1; BREAST CANCER; FEBRILE NEUTROPENIA; FEC CHEMOTHERAPY; MRP1; SINGLE-NUCLEOTIDE POLYMORPHISMS;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; EPIRUBICIN; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; GENETIC VARIATION; HEMATOLOGIC DISEASES; HUMANS; MIDDLE AGED; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOADJUVANT THERAPY; POLYMORPHISM, SINGLE NUCLEOTIDE; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES;

EID: 84878435556     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt008     Document Type: Article

References (63)

1. Roché H, Fumleau P, Spielmann M et al. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients. The FNCLCC PACS 01 Trial. J Clin Oncol 2006; 24: 5664-5671.
2. Ganz PA, Kwan L, Stanton AL et al. Physical and psychosocial recovery in the year after primary treatment of breast cancer. J Clin Oncol 2011; 9: 1101-1109.
3. Hasset MJ, O'Malley AJ, Pakes JR et al. Frequency and cost of chemotherapyrelated serious adverse effects in a population sample of women with breast cancer. J Natl Cancer Inst 2006; 98: 1108-1117.
4. Felici A, Verweij J, Sparreboom A. Dose strategies for anticancer drugs: the good, the bad and body-surface area. Eur J Cancer 2002; 38: 1677-1684.
5. Rudek MA, Sparreboom A, Garrett-Mayer ES et al. Factors affecting pharmacokinetic variability following doxorubicin and docetaxel-based therapy. Eur J Cancer 2004; 40: 1170-1178.
6. Canal P, Chatelut E, Guichard S et al. Practical treatment guide for dose individualisation in cancer chemotherapy. Drugs 1998; 56: 1019-1038.
7. Ranson MR, Scarffe JH. Population and Bayesian pharmacokinetics in oncology. Clin Oncol (R Coll Radiol) 1994; 6: 254-260.
8. Rosner GL, Hargis JB, Hollis DR et al. Relationship between toxicity and obesity in women receiving adjuvant chemotherapy for breast cancer: results from cancer and leukemia group B study 8541. J Clin Oncol 1996; 14: 3000-3008.
9. Griggs JJ, Mangu PB, Anderson H et al. Appropriate chemotherapy dosing for obese adult patients with cancer: American society of clinical oncology clinical practice guideline. J Clin Oncol 2012; 30: 1153-1161.
10. Di Paolo A, Danesi R, Vannozi F et al. Limited sampling model for the analysis of 5-fluorouracil pharmacokinetics in adjuvant chemotherapy for colorectal cancer. Clin Pharmacol Ther 2002; 72: 627-637.
11. Launay MC, Milano G, Iliadis A et al. A limited sampling procedure for estimating Adriamycin pharmacokinetics in cancer patients. Br J Cancer 1989; 60: 89-92.
12. Marchiset-Leca D, Leca FR, Galeani A et al. A limited sampling strategy for the study of pirarubicin pharmacokinetics in humans. Cancer Chemother Pharmacol 1995; 36: 233-238.
13. Aapro MS, Cameron DA, Pettengell R et al. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapyinduced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 2006; 42: 2433-2453.
14. Kafka A, Sauer G, Jaeger C et al. Polymorphism C3435T of the MDR-1 predicts response to preoperative chemotherapy in locally advanced breast cancer. Int J Oncol 2003; 22: 1117-1121.
15. Semsei AF, Erdelyi DJ, Ungvari I et al. ABCC1 polymorphisms in anthracycline induced cardiotoxicity in childhood acute lymphoblastic leukemia. Cell Biol Int 2012; 36: 79-86.
16. Visscher H, Ross CJ, Rassekh SR et al. Pharmacogenomic Prediction of anthracycline-induced cardiotoxicity in children. J Clin Onc 2012; 30: 1422-1428.
17. Wojnowski L, Kulle B, Schirmer M et al. NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicininduced cardiotoxicity. Circulation 2005; 112: 3754-3762.
18. Van Kuilenburg AB, Haasjes J, Richel DJ et al. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5- fluorouracil-associated toxicity: identification of new mutations in the DPD gene. Clin Cancer Res 2000; 6: 4705-4712.
19. Van Kuilenburg AB. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur J Cancer 2004; 40: 939-950.
20. Van Kuilenbrug AB, Muller EW, Haasjes J et al. Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14+1G >A mutation causing DPD deficiency. Clin Cancer Res 2001; 7: 1149-1153.
21. Takimoto CH, Lu ZH, Zhang R et al. Severe neurotoxicity following 5-fluorouracilbased chemotherapy in a patient with dihydropyrimidine dehydrogenase deficiency. Clin Cancer res 1996; 2: 477-481.
22. Raida M, Schwabe W, Hausler P et al. Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5FU)-related toxicity compared with controls. Clin Cancer res 2001; 7: 2832-2839.
23. Morel A, Boisdron-celle M, Fey L et al. Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance. Mol Cancer ther 2006; 5: 2895-2904.
24. Sohn KJ, Croxford R, Yates Z et al. Effect of the methylenetetrahydrofolate reductase C677T polymorphism on chemosensitivity of colon and breast cancer cells to 5-fluorouracil and methotrexate. J Natl Cancer Inst 2004; 96: 134-144.
25. Etienne-Grimaldi MC, Milano G, Maindrault-Goebel F et al. Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and FOLFOX response in colorectal cancer patients. Br J Clin Pharmacol 2010; 69: 58-66.
26. Nakajima M, Komagata S, Fujiki Y et al. Genetic polymorphisms of CYP2B6 affect the pharmacokinetics/pharmacodynamics of cyclophosphamide in japanese cancer patients. Pharmacogenet Genom 2007; 17: 431-445.
27. Rocha V, Porcher R, Fernandes JF et al. Association of drug metabolism gene polymorphisms with toxicities, graft-versus-host disease and survival after HLAidentical sibling hematopoietic stem cell transplantation for patients with leukemia. Leukemia 2008; 23: 545-556.
28. Bray J, Sludden J, Griffin MJ et al. Influence of pharmacogentics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide. Br J Cancer 2010; 102: 1003-1009.
29. Gor PP, Su HI, Gray RJ et al. Cyclophosphamide-metabolizing enzyme polymorphisms and survival outcomes after adjuvant chemotherapy for node-positive breast cancer: a retrospective cohort study. Breast Cancer Res 2010; 12: R26.
30. Udler M, Maia AT, Cebrian A et al. Common germline genetic variation in antioxidant defense genes and survival after diagnosis of breast cancer. J Clin Oncol 2007; 25: 3015-3023.
31. Sweeney C, Ambrosone CB, Joseph L et al. Association between a glutathione S-transferase A1 promoter polymorphism and survival after breast cancer treatment. Int J Cancer 2003; 103: 810-814.
32. Zhong S, Huang M, Yang X et al. Relationship of glutathione S-transferase genotypes with side-effects of pulsed cyclophosphamide therapy in patients with systemic lupus erythematosus. Br J Clin Pharmacol 2006; 62: 457-472.
33. Thussbas C, Nahrig J, Streit S et al. FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer. J Clin Oncol 2006; 24: 3747-3755.
34. Fagerholm R, Hofstetter B, Tommiska J et al. NAD(P)H: quinone oxidoreductase 1 NQO1*2 genotype (P187S) is a strong prognostic and predictive factor in breast cancer. Nat Genet 2008; 40: 844-853.
35. Bewick MA, Conlon MS, Lafrenie RM et al. Polymorphisms in manganese superoxide dismutase, myeloperoxidase and glutathione-S-transferase and survival after treatment for metastatic breast cancer. Breast Cancer Res Treat 2008; 111: 93-101.
36. Marsh S, Mcleod HL. Thymidylate synthase pharmacogenetics in colorectal cancer. Clin Colorectal Cancer 2001; 1: 175-178.
37. Sun Z, Chen J, Aakre J et al. Genetic variation in glutathione metabolism and DNA repair genes predicts survival of small-cell lung cancer patients. Ann Oncol 2010; 21: 2011-2016.
38. Jaremko M, Justenhoven C, Schroth W et al. Polymorphism of the DNA repair enzyme XRCC1 is associated with treatment prediction in anthracycline and cyclophosphamide/methotrexate/5-fluorouracil-based chemotherapy of patients with primary invasive breast cancer. Pharmacogenet Genomics 2007; 17: 529-538.
39. Lai JI, Tzeng CH, Chen PM et al. Very low prevalence of XPD K751Q polymorphism and its association with XPD expression and outcomes of FOLFOX- 4 treatment in Asian patients with colorectal carcinoma. Cancer Sci 2009; 100: 1261-1266.
40. Khrunin AV, Moisseev A, Gorbunova V et al. Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients. Pharmacogenomics J 2010; 10: 54-61.
41. Clarke L, Zheng-Bradley X, Smith R et al. The 1000 Genomes Project: data management and community access. Nat Methods 2012; 9: 459-462.
42. Reumers J, De Rijk P, Zhao H et al. Optimized filtering reduces the error rate in detecting genomic variants by short-read sequencing. Nat Biotechnol 2011; 30: 61-68.
43. Sun L, Craiu RV, Paterson AD et al. Stratified false discovery control for largescale hypothesis testing with application to genome-wide association studies. Genet Epidemiol 2006; 30: 519-530.
44. Dean M, Rzhetsky A, Allikmets R. The human ATP-binding cassette (ABC) transporter superfamily. Genome Res 2001; 11: 1156-1166.
45. Cole SP, Bhardwaj G, Gerlach JH et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992; 258: 1650-1654.
46. Flens MJ, Zaman GJ, van der Valk P et al. Tissue distribution of the multidrug resistance protein. Am J Pathol 1996; 148: 1237-1247.
47. Zhou SF, Wang LL, Di YM et al. Substrates and inhibitors of human multidrug resistance associated proteins and the implications in drug development. Curr Med Chem 2008; 15: 1981-2039.
48. Wu Z, Li X, Zeng Y et al. In vitro and in vivo inhibition of MRP gene expression and reversal of multidrug resistance by siRNA. Basic Clin Pharmacol Toxicol 2011; 108: 177-184.
49. Jungsuwadee P, Zhao T, Stolarczyk El et al. The G671V variant of MRP1/ABCC1 links doxorubicin-induced acute cardiac toxicity to disposition of the glutathione conjugate of 4-hydroxy-2-trans-nonenal. Pharmacogenet Genomics 2012; 22: 273-284.
50. Aapro MS, Bohlius J, Cameron DA et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 2011; 47: 8-32.
51. Wildiers H, Reiser M. Relative dose intensity of chemotherapy and its impact on outcomes in patients with early breast cancer or aggressive lymphoma. Crit Rev Oncol Hematol 2011; 77: 221-240.
52. Duguay Y, Baar C, Skorpen F et al. A novel functional polymorphism in the uridine diphosphate-glucuronosyltransferase 2B7 promoter with significant impact on promoter activity. Clin Pharmacol Ther 2004; 75: 223-233.
53. Rossi D, Rasi S, Franceschetti S et al. Analysis of the host pharmacogenetic background for prediction of outcome and toxicity in diffuse large B-cell lymphoma treated with R-CHOP21. Leukemia 2009; 23: 1118-1126.
54. Cecchin E, D'Andrea M, Lonardi S et al. A prospective validation pharmacogenomic study in the adjuvant setting of colorectal cancer patients treated with the 5- fluorouracl/leucovorin/oxaliplatin (FOLFOX4) regimen. Pharmacogenomics J 2012; Aug 7 [Epub ahead of print], doi: 10.1038/tpj.2012.31
55. Hampras SS, Sucheston L, Weiss J et al. Genetic polymorphisms of ATP-binding cassette (ABC) proteins, overall survival and drug toxicity in patients with acute myeloid leukemia. Int J Mol Epidemiol Genet 2010; 1: 201-207.
56. Ekhart C, Rodenhuis S, Smits PH et al. Relations between polymorphisms in drugmetabolising enzymes and toxicity of chemotherapy with cyclophosphamide, thiotepa and carboplatin. Pharmacogenet Genomics 2008; 18: 1009-1015.
57. Kirchheiner J, Meineke I, Fuhr U et al. Impact of genetic polymorphisms in CYP2C8 and rosiglitazone intake on the urinary excretion of dihydroxyeicosatrienoic acids. Pharmacogenomics 2008; 9: 277-288.
58. Bosch TM, Meijerman I, Beijnen JH et al. Genetic polymorphisms of drugmetabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer. Clin Pharmacokinet 2006; 45: 253-285.
59. Timm R, Kaiser R, Lötsch J et al. Association of cyclophosphamide pharmacokinetics to polymorphic cytochrome P450 2C19. Pharmacogenomics J 2005; 5: 365-373.
60. Takada K, Arefayene M, Desta Z et al. Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis. Arthritis Rheum 2004; 50: 2202-2210.
61. Van Schaik RH, Van der Heiden IP, Van den Anker JN et al. CYP3A5 variant allele frequencies in Dutch Caucasians. Clin Chem 2002; 48: 1668-1671.
62. Tian JN, Ho IK, Tsou HH et al. UGT2B7 genetic polymorphisms are associated with the withdrawal symptoms in methadone maintenance patients. Pharmacogenomics 2012; 13: 879-888.
63. Marcos EC, Garcia A, Reguero V et al. Germline Single Nucleotide Polymorphims (SNPS) in XRCC3, XRCC1 and XPD and survival outcomes after adjuvant chemotherapy in early breast cancer patients. J Clin Oncol 2010; 28: 15s. (suppl; abstr 619).